TrialsgrambetaRCTs are beautiful

Pulmonary hypertension & congenital heart disease

7 trials
  • 2025ZENITHActivin signallingIn 172 patients with high-risk pulmonary arterial hypertension, sotatercept reduced death, lung transplantation or heart-failure hospitalisation compared with placebo.
  • 2023STELLARActivin signallingIn 323 patients with pulmonary arterial hypertension, sotatercept added to background therapy improved 6-minute walk distance compared with placebo.
  • 2020FUELFontan circulationIn 400 adolescents with Fontan circulation, udenafil did not significantly improve peak oxygen consumption compared with placebo, although exercise performance at the ventilatory anaerobic threshold improved.
  • 2019MAESTROEisenmenger syndromeIn 226 patients with Eisenmenger syndrome in WHO functional class II–III, macitentan did not improve 6-minute walk distance compared with placebo.
  • 2015AMBITIONCombination therapyIn 500 patients with pulmonary arterial hypertension, initial ambrisentan plus tadalafil reduced clinical-failure events compared with monotherapy.
  • 2013SERAPHINEndothelin antagonistsIn 742 patients with pulmonary arterial hypertension, macitentan reduced morbidity and mortality events compared with placebo.
  • 2006BREATHE-5Eisenmenger syndromeIn 54 patients with WHO functional class III Eisenmenger syndrome, bosentan lowered pulmonary vascular resistance and improved 6-minute walk distance without worsening systemic oxygen saturation compared with placebo.